Skip to main content

Warnex to Sell Analytical Services Division

NEW YORK (GenomeWeb News) – Warnex today said that it has inked an agreement with an unnamed private company to purchase Warnex's Analytical Services division for more than C$1.1 million (US$1.1 million).

The deal comes around a week after Warnex sold its medical laboratories division to Gamma-Dynacare Medical Laboratories for C$7.5 million (US$7.3 million).

The Analytical Services division provides pharmaceutical and biotech firms with quality control services including chromatography, microbiology, and method development and validation. Laval, Quebec-based Warnex expects to close the deal around Jan. 15, 2012.

Warnex will receive C$400,000 in cash and an additional cash payment equal to the working capital of the division on the closing date, which is expected to be roughly C$700,000. In addition, Warnex will receive a 15 percent passive equity interest in the acquirer, and "other valuable consideration," it said.

"This transaction is consistent with our strategic plan and the commitment we made to reduce long-term debt," Michael Singer, chairman of the executive committee of the board of directors, said in a statement. "It also allows us to retain substantial upside in the Analytical Services business that we pioneered."

The Scan

UK Funds to Stay Ahead of Variants

The UK has announced a further £29.3 million to stay on top of SARS-CoV-2 variants, the Guardian reports.

Push for Access

In a letter, researchers in India seek easier access to COVID-19 data, Science reports.

Not as Cold

Late-stage trial results are expected soon for an RNA-based vaccine that could help meet global demand as it does not require very cold storage, the New York Times writes.

Genome Research Papers on Microbes' Effects on Host Transfer RNA, Honeybee Evolution, Single-Cell Histones

In Genome Research this week: influence of microbes on transfer RNA patterns, evolutionary relationships of honeybees, and more.